Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.82 |
| ▸ | HTR2A | P28223 | 3/20 | 0.82 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | HTR7 | P34969 | 1/20 | 0.82 |
| ▸ | HTR6 | P50406 | 1/20 | 0.82 |
| ▸ | MAOA | P21397 | 7/20 | 0.66 |
| ▸ | MAOB | P27338 | 7/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842045 | 0.97 | DRD2 (0.87) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL1835500 | 0.96 | DRD2 (0.78) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL1834721 | 0.86 | DRD2 (0.70) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL1836906 | 0.86 | DRD2 (0.70) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL27804329 | 0.85 | HTR2A (0.63) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL1839696 | 0.83 | DRD2 (0.69) | DRD2HTR2AHTR1AHTR7HTR6 | |
| SCHEMBL1842068 | 0.83 | DRD2 (0.69) | DRD2HTR2AHTR1AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL15473534 | 0.82 | DRD2 (0.68) | DRD2HTR2AHTR1AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL15473625 | 0.82 | DRD2 (0.68) | DRD2HTR2AHTR1AHTR7HTR6 | |
| Aripiprazole SCHEMBL1043439 | 0.82 | DRD2 (0.67) | DRD2HTR2AHTR1AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653069-B2 | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-02-18 | — | — | US | claimed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | claimed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | claimed |
| US-8653069-B2 | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-02-18 | — | — | US | disclosed |
| CN-101693711-B | 3-(1-piperazinyl)-1,2-benzisothiazole derivative as well as synthesizing method and application thereof | YUMIN DU | 2011-08-17 | — | — | CN | disclosed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | disclosed |
| CN-101693711-A | 3-(1-piperazinyl)-1,2-benzisothiazole derivative as well as synthesizing method and application thereof | YUMIN DU | 2010-04-14 | — | — | CN | disclosed |
| CN-101607959-A | The dihydroquinoline ketone derivatives, its preparation method and be the pharmaceutical composition of activeconstituents with this compound | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | REN, GRIK5, CAT | DRD2 15/4885HTR2A 425/4885HTR1A 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.